Each week we highlight five things affecting the life sciences industry. Here’s the latest.
FDA announces plan to reclassify at least a dozen peptides
- This plan includes removing peptides from Category 2 (which flags significant safety concerns) and potentially shifting them into a more permissive category that allows mass production by compounding pharmacies.
- According to Endpoints News, the decision could materially benefit telehealth and compounding pharmacy markets as formal advisory committee meetings are scheduled later this year to discuss the reclassification details.
FDA takes first step in its enforcement of clinical trial reporting
- The U.S. Food and Drug Administration said results are missing for about 30% of studies on ClinicalTrials.gov and has sent messages to roughly 2,200 clinical trial sponsors urging them to report overdue data, citing concerns that incomplete reporting skews perceptions of drug safety and effectiveness.
- The outreach marks an initial enforcement step, with the agency seeking voluntary compliance but warning that continued noncompliance could lead to formal notices and potential fines, reinforcing long‑standing requirements to report most trial results within one year of study completion, reports Fierce Biotech.
Biotech IPOs begin to pick back up in Q2
- Two biotech companies filed for initial public offerings late last week, adding momentum to a reopening biotech IPO window alongside recent filings and offerings as improving biotech stock performance and pharma deal activity boost investor appetite.
- The filings spotlight differentiated pipelines targeting high‑unmet‑need indications, with one advancing mid‑stage neuroscience programs for depression and anxiety, and the other developing novel antibody therapies for rare bleeding disorders with no approved preventive treatments, according to Endpoints News.
Medtech company agrees to go-private deal
- A medtech company agreed to be acquired by a private equity firm in a $1.27 billion all‑cash go‑private deal, representing an approximate 72% premium to its prior closing share price and ending its run as a public company.
- The transaction follows the company’s recent portfolio reshaping and increased focus on higher‑growth specialty nutrition and pain management businesses, with leadership citing greater flexibility and resources under private ownership to advance innovation and long‑term growth, reports Medtech Dive.
UK government announces more than £80 million in new life sciences manufacturing investments
- These investments were unlocked through the Life Sciences Innovative Manufacturing Fund to strengthen domestic production of vital medicines, support over 500 highly skilled jobs and advance the government’s life sciences sector plan.
- The funding supports expanded production of vaccines and treatments for conditions such as cancer, bipolar disorder and neurodegenerative diseases, with major investments from companies to boost innovation, supply chain resilience and regional life sciences clusters across the UK.
For more insights in life sciences, check out RSM’s industry outlook.
